October 29, 2026
Glycorex Transplantation AB (publ) today announces a strategic expansion of its business. Through its subsidiary, Glycorex Universal Blood Products (UBP), the company aims to develop and supply standardized, universal blood products for civilian healthcare, emergency preparedness and military medical applications.
Modern blood supply chains face significant logistical challenges, including the limited availability of universal AB plasma. Recent studies from NHS Blood and Transplant in the UK demonstrate strong hospital interest in universal blood components to improve patient safety, simplify logistics and reduce waste.
Building on its established and CE-marked Glycosorb technology, Glycorex is taking the next step from supplying blood group antibody removal technology towards developing scalable production and supply of ready-to-use universal plasma products with consistently low anti-A/B antibody titers. This could significantly simplify blood supply logistics, particularly in prehospital emergency care and military medicine.
“By broadening our strategy, we are taking a natural and decisive step to apply our established adsorption technology to one of healthcare’s most critical logistical challenges. With over 25 years of clinical experience in selective blood group antibody removal for ABO-incompatible transplantation, combined with recent results from our collaborations with civil and military institutions in transfusion medicine, we have a strong foundation for developing universal blood products. Our ambition is to build a new commercial platform that addresses important needs in civilian healthcare and military preparedness, while creating significant long-term growth opportunities for Glycorex,” says Carl-Magnus Schultz, CEO.
The initiative will initially focus on process development, scientific and clinical validation, and regulatory requirements in collaboration with leading Nordic experts in transfusion medicine, with the objective of establishing a commercially scalable platform for universal blood products.
For more information, please contact:
Carl-Magnus Schultz, CEO
Email: carl.schultz@glycorex.com, Phone: +46 46 286 52 30
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company’s focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets.
Product development and production takes place in the company’s own facility in Lund, Sweden.
Glycosorb® ABO is one of the company’s self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient’s plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 8,000 transplants in over 30 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.